Back to top

Analyst Blog

Agilent Technologies Inc. (A - Analyst Report) has won the patent for comparative genomic hybridization (CGH) methods in the U.S.

CGH methods facilitate the basic and clinical study of genetics and cancer.  Being a method of studying genes, it can also help to detect other diseases like developmental delays, mental retardation and autism in children.

The study of genes has gained popularity in medical research because many so-called incurable diseases appear to have their roots in unfavorable genetics. The most important aspect of genome testing is that it can detect disease in its early stages, thus facilitating better diagnosis.

The genetic testing market is, therefore, entering an exciting era where it can play a vital role in detecting diseases like cancer, cystic fibrosis and Alzheimer’s and many other life-threatening diseases.

Agilent has been increasing its focus in the medial diagnostics segment because of the significant growth potential in the area. The company recently acquired a Danish cancer diagnostics company, Dako, for $2.2 billion. Dako deals in antibodies, scientific instruments and software used mainly in cancer-related diagnostic labs. It also collaborates with drug companies for the development of methods to identify patients likely to benefit from certain therapies.

In the health care sector, major players such as Abbott Laboratories (ABT - Analyst Report), Genomic Health Inc. (GHDX - Analyst Report), Life Technologies Corporation and others have all increased focus on the genetic testing market.

Agilent’s revenue in the third quarter was flat sequentially and up 1.9% year over year, short of management’s expectations for a 2-3% sequential increase ($1.77 billion to $1.79 billion). The Chemical Analysis segment generated 22.0% of third quarter revenue, down 8.8% sequentially and 7.0% year over year. The sequential decline was largely because of weakness in food testing, although chemical/energy was also down significantly and the forensics/environmental was flat. All three markets fared similarly when compared with the year-ago quarter. The newly- added Diagnostics and Genomics segment accounted for 6% of revenue in this quarter.

Currently, Agilent Technologies Inc. has a Zacks Rank of #3, implying a short-term ‘Hold’ recommendation.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%